Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Sarepta (SRPT) to $38 from $45 and keeps an Overweight rating on the shares. Given 2026 guidance, it seems the GTx launch reset post safety events could take longer than the firm expected. Therefore, Wells adjusts its ELEVIDYS numbers arriving at a new price target That said, the firm expects the siRNA readout to be positive and thus the setup is still favorable.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta price target lowered to $20 from $22 at Baird
- Sarepta downside risks outweigh upside potential, says Citi
- Cut Guidance, Clinical Uncertainty, and PMO Franchise Risk Underscore Negative Risk–Reward for Sarepta
- Maintaining Hold on Sarepta: Weaker Elevidys Outlook, Competitive PMO Pressures, and CEO Transition Temper Near‑Term Upside
- Sarepta CEO to retire